Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 12Myeloid 4Lymphoid 2

Conditions

Mastocytosis, Systemic 2Leukemia, Mast-Cell 2Aggression 2Leukemia 1

Interventions

Rituximab 689Cyclophosphamide 615Vincristine 285Etoposide 272Doxorubicin 271Cytarabine 230Prednisone 229Methotrexate 221fludarabine phosphate 189Filgrastim 187Dexamethasone 180fludarabine 176Lenalidomide 165Radiotherapy 128Melphalan 127Peripheral Blood Stem Cell Transplantation 123Busulfan 118Bendamustine Hydrochloride 116Granulocyte Colony-Stimulating Factor 113Bortezomib 112ibrutinib 111Mycophenolic Acid 110venetoclax 106Whole-Body Irradiation 106obinutuzumab 105Tacrolimus 105Gemcitabine 92zanubrutinib 81Specimen Handling 80Cyclosporine 76

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × midostaurin × Lymphoid × Clear all
NCT00782067 2018-11-15

Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia

Novartis

Phase 2 Completed
116 enrolled 16 charts
LymphoidMyeloidOther hematologic neoplasm

Aggression, Leukemia, Leukemia, Mast-Cell, Mastocytosis, Systemic

NCT00233454 2018-09-20

Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia

Stanford University

Phase 2 Completed
26 enrolled 12 charts
LymphoidMyeloidOther hematologic neoplasm

Aggression, Leukemia, Mast-Cell, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡